PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.72%
EBIT growth of 32.72% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
-21.99%
Negative operating income growth while Biotechnology median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
32.68%
Net income growth of 32.68% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
32.51%
EPS growth of 32.51% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
32.51%
Diluted EPS growth of 32.51% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Negative OCF growth while Biotechnology median is -7.17%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-20.05%
Negative FCF growth while Biotechnology median is -5.01%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-102666.73%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-29000.87%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
0.57%
3Y OCF/share growth of 0.57% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-765363.95%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-27613.67%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-208.91%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
82516.86%
Equity/share CAGR of 82516.86% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
5226.69%
5Y equity/share CAGR of 5226.69% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
1660.30%
3Y equity/share CAGR of 1660.30% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-8.72%
Negative BV/share change while Biotechnology median is -7.05%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-32.96%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
44.99%
R&D growth of 44.99% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-4.08%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.